CluenexQiagen QGEN
Qiagen scores average on business quality (5.7 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Qiagen does
Qiagen sells sample and assay technologies to molecular testing labs, hospitals, and pharmaceutical researchers, converting biological samples into actionable molecular insights. The company is leaning into its QIAstat-Dx portfolio, securing fresh FDA clearances to drive adoption in decentralized hospital settings.
- What it does best
Qiagen dominates sample preparation through embedded workflows that labs rarely switch. Its consumables drive recurring revenue across a massive installed base, yielding an operating margin in the top quartile of its sector at 24.9%.
- The main risk
With revenue growth languishing at a sluggish 5.6% and lagging sector peers, Qiagen faces the constant threat of commoditization in basic assay testing as hospital budgets tighten and larger diagnostics players crowd its menu.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin rests at 24.9% with a free cash flow margin near 21%, supported by high-margin consumables. The business generates reliable cash as it scales, though growth remains muted.
Qiagen holds customer lock-in via proprietary sample prep kits and instruments embedded in hospital workflows, reflected by an operating margin sitting in the top quartile at the 76th sector percentile.
Revenue growth stands at 5.6%, crawling in the bottom quartile of its sector at the 32nd percentile. Momentum is barely budging compared to its historical peaks.
Debt sits at $1.7B with a comfortable interest coverage of 13x, making debt service manageable. Free cash flow reached $440M alongside $497M in buybacks, reflecting reliable cash conversion.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on QGEN
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Qiagen scores average on the Cluenex quality check (5.7 of 10), measured against its own industry. Profitability is fair, moat fair, growth slow and financial health strong.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 2, 2026, after the close.
See QGEN today
- Today's verdict on QGEN, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Qiagen (QGEN)”, https://cluenex.com/stocks/qgen/, data as of Oct 10, 2026.